61. Autoimmune hemolytic anemia Clinical trials / Disease details


Clinical trials : 146 Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2022-001773-31-ES
(EUCTR)
14/02/202311/10/2022A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic aneamiaA phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA) - VAYHIA warm autoimmune haemolytic anaemia (wAIHA)
MedDRA version: 25.0;Level: LLT;Classification code 10047822;Term: Warm type haemolytic anaemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Ianalumab
Product Code: VAY736
INN or Proposed INN: Ianalumab
Novartis Farmacéutica, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 3Argentina;Singapore;Hungary;United States;Japan;United Kingdom;Malaysia;Thailand;Spain;India;China;Taiwan;Italy;Israel;Australia;France;Germany
2NCT05648968
(ClinicalTrials.gov)
December 30, 202223/11/2022A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of TreatmentWarm Autoimmune Hemolytic Anemia (wAIHA)Biological: Ianalumab;Drug: PlaceboNovartis PharmaceuticalsNULLRecruiting18 YearsN/AAll90Phase 3Singapore